{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:37:20Z","timestamp":1791999440807,"version":"4.4.0"},"reference-count":20,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Sodium-glucose transport protein 2 inhibitors (SGLT2i) slow the progression of renal dysfunction and improve the prognosis of patients with heart failure. Amyloidosis constitutes an important subgroup for which evidence is lacking. Amyloidotic fibrils originating from misfolded transthyretin and light chains are the causal agents in ATTR and AL amyloidosis. In these most frequent subtypes, cardiac involvement is the most common organ manifestation. Because cardiac and renal function frequently deteriorate over time, even under best available treatment, SGLT2i emerge as a promising treatment option due to their reno- and cardioprotective properties. We retrospectively analyzed patients with cardiac amyloidosis, who received either dapagliflozin or empagliflozin. Out of 79 patients, 5.1% had urinary tract infections; 2 stopped SGLT2i therapy; and 2.5% died unrelated to the intake of SGLT2i. No genital mycotic infections were observed. As expected, a slight drop in the glomerular filtration rate was noted, while the NYHA functional status, cardiac and hepatic function, as well as the 6 min walk distance remained stable over time. These data provide a rationale for the use of SGLT2i in patients with amyloidosis and concomitant cardiac or renal dysfunction. Prospective randomized data are desired to confirm safety and to prove efficacy in this increasingly important group of patients.<\/jats:p>","DOI":"10.3390\/jcm13010283","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T04:05:38Z","timestamp":1704341138000},"page":"283","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Safety and Tolerability of SGLT2 Inhibitors in Cardiac Amyloidosis\u2014A Clinical Feasibility Study"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3644-9187","authenticated-orcid":false,"given":"Maximilian J.","family":"Steinhardt","sequence":"first","affiliation":[{"name":"Interdisciplinary Amyloidosis Center of Northern Bavaria, University Hospital W\u00fcrzburg, 97080 W\u00fcrzburg, Germany"},{"name":"Department of Internal Medicine II, University Hospital W\u00fcrzburg, 97080 W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4393-1772","authenticated-orcid":false,"given":"Vladimir","family":"Cejka","sequence":"additional","affiliation":[{"name":"Interdisciplinary Amyloidosis Center of Northern Bavaria, University Hospital W\u00fcrzburg, 97080 W\u00fcrzburg, Germany"},{"name":"Department of Internal Medicine I, University Hospital W\u00fcrzburg, 97080 W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Hospital W\u00fcrzburg, 97080 W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"B\u00e4uerlein","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Hospital W\u00fcrzburg, 97080 W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Sch\u00e4fer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Hospital W\u00fcrzburg, 97080 W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Adrah","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Hospital W\u00fcrzburg, 97080 W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra M.","family":"Ihne-Schubert","sequence":"additional","affiliation":[{"name":"Interdisciplinary Amyloidosis Center of Northern Bavaria, University Hospital W\u00fcrzburg, 97080 W\u00fcrzburg, Germany"},{"name":"Department of Internal Medicine II, University Hospital W\u00fcrzburg, 97080 W\u00fcrzburg, Germany"},{"name":"CIRCLE\u2014Centre for Innovation Research, University Lund, 22362 Lund, Sweden"},{"name":"Department of Internal Medicine IV, University Hospital Gie\u00dfen, 35392 Gie\u00dfen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Papagianni","sequence":"additional","affiliation":[{"name":"Interdisciplinary Amyloidosis Center of Northern Bavaria, University Hospital W\u00fcrzburg, 97080 W\u00fcrzburg, Germany"},{"name":"Department of Neurology, University Hospital W\u00fcrzburg, 97080 W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7011-0286","authenticated-orcid":false,"given":"K. Martin","family":"Kort\u00fcm","sequence":"additional","affiliation":[{"name":"Interdisciplinary Amyloidosis Center of Northern Bavaria, University Hospital W\u00fcrzburg, 97080 W\u00fcrzburg, Germany"},{"name":"Department of Internal Medicine II, University Hospital W\u00fcrzburg, 97080 W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0920-6094","authenticated-orcid":false,"given":"Caroline","family":"Morbach","sequence":"additional","affiliation":[{"name":"Interdisciplinary Amyloidosis Center of Northern Bavaria, University Hospital W\u00fcrzburg, 97080 W\u00fcrzburg, Germany"},{"name":"Department of Internal Medicine I, University Hospital W\u00fcrzburg, 97080 W\u00fcrzburg, Germany"},{"name":"Department Clinical Research & Epidemiology, Comprehensive Heart Failure Center, University Hospital W\u00fcrzburg, 97080 W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1771-7249","authenticated-orcid":false,"given":"Stefan","family":"St\u00f6rk","sequence":"additional","affiliation":[{"name":"Interdisciplinary Amyloidosis Center of Northern Bavaria, University Hospital W\u00fcrzburg, 97080 W\u00fcrzburg, Germany"},{"name":"Department of Internal Medicine I, University Hospital W\u00fcrzburg, 97080 W\u00fcrzburg, Germany"},{"name":"Department Clinical Research & Epidemiology, Comprehensive Heart Failure Center, University Hospital W\u00fcrzburg, 97080 W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2215\/CJN.04010609","article-title":"Familial renal glucosuria and SGLT2: From a mendelian trait to a therapeutic target","volume":"5","author":"Santer","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ejhf.1432","article-title":"A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/CIRCULATIONAHA.122.059785","article-title":"Empagliflozin for Heart Failure with Preserved Left Ventricular Ejection Fraction With and Without Diabetes","volume":"146","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","article-title":"Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e009837","DOI":"10.1161\/CIRCHEARTFAILURE.122.009837","article-title":"Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials","volume":"16","author":"Nassif","year":"2023","journal-title":"Circ. Heart Fail."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Baigent","year":"2022","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41569-022-00824-4","article-title":"SGLT2 inhibitors: Role in protective reprogramming of cardiac nutrient transport and metabolism","volume":"20","author":"Packer","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: Mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.hrthm.2021.03.028","article-title":"Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials","volume":"18","author":"Fernandes","year":"2021","journal-title":"Heart Rhythm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1681\/ASN.2018010103","article-title":"Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial","volume":"29","author":"Wanner","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/ckj\/sfy090","article-title":"The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: A rationale for the EMPA-KIDNEY study","volume":"11","author":"Herrington","year":"2018","journal-title":"Clin. Kidney J."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group (2022). KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int., 102, S1\u2013S127.","DOI":"10.1016\/j.kint.2022.06.008"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2337\/dc18-2207","article-title":"Ambulatory Blood Pressure Reduction With SGLT-2 Inhibitors: Dose-Response Meta-analysis and Comparative Evaluation With Low-Dose Hydrochlorothiazide","volume":"42","author":"Georgianos","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/dom.13531","article-title":"Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors","volume":"21","author":"Dave","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2215\/CJN.08720811","article-title":"Transthyretin amyloidosis and the kidney","volume":"7","author":"Lobato","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ehf2.14188","article-title":"SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: Early tolerance and clinical response to dapagliflozin","volume":"10","author":"Dobner","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Uitrakul, S., Aksonnam, K., Srivichai, P., Wicheannarat, S., and Incomenoy, S. (2022). The Incidence and Risk Factors of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Using SGLT2 Inhibitors: A Real-World Observational Study. Medicines, 9.","DOI":"10.3390\/medicines9120059"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"EMPA-Kidney Collaborative Group (2022). Empagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med., 388, 117\u2013127.","DOI":"10.1056\/NEJMoa2204233"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/1\/283\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:39:38Z","timestamp":1760103578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/1\/283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["jcm13010283"],"URL":"https:\/\/doi.org\/10.3390\/jcm13010283","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]}}}